Solutions in Plastic Surgery

Advanced Placental-Based Allografts When Patients Are in Need

Providing Protective Barriers and Environments that Support the Healing Cascade

There are many risk-factors to healing such as patient co-morbidities and complex defects.1 MIMEDX offers an array of advanced placental-based allografts that may be used in a variety of surgical applications to provide valuable benefits in patient care. 


  • Provide a protective barrier and environment that supports the healing cascade
  • Protect the wound bed to aid in the development of granulation tissue 
  • Provide a human biocompatible extracellular matrix (ECM) and contain 250+ regulatory proteins2-5


    • A lyophilized, biocompatible, and human extracellular matrix derived from the placental disc.
    • For use in the replacement or supplementation of damaged or inadequate integumental tissue.
    • Versatile and easy to use: apply dry or hydrated as a paste.
    • Early scientific data in a nude mouse model shows AXIOFILL supports site appropriate function in tissue by allowing cell attachment, new collagen formation on the matrix, and new blood vessel formation.6

    Clinical Use Examples:

      • Acute and chronic wounds
      • Debridements
      • Exposed bone and tendon
      • Dehiscence
      • Decubitus ulcers
      • Flaps
      • Bridge to STSG
      • Limb salvage

      Case Studies:
      How Physicians Use Our Products

      Case study 1

      Acute Abdominal Wall Dehiscence With EPIFIX7


      62-year-old obese male, BMI of 29, type II diabetes, with a history of hypertension, myocardial infarction with stent placements, multiple abdominal surgeries, and over forty years of cigarette smoking, underwent large ventral hernia repair. At one week post op, the patient developed ischemia at the incision line, which led to an incisional dehiscence.

      Studies have shown a direct correlation between the number of comorbidities and clinical outcomes. A significant rise in complications, length of stay, and mortality rates is associated with the rise in number of patient comorbidities.8-10

      Surgical Intervention

      The patient was managed with serial debridement and wet-to-dry dressings for two months, then placed on negative pressure wound therapy (NPWT) for four weeks at home. After one month of NPWT, the wound had only decreased by 30%. NPWT was discontinued, and DHACM (Dehydrated Human Amnion/Chorion Membrane) was applied every other week, instead of weekly, due to the travel distance for the patient. The product provides a barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. It provides a biocompatible human extracellular matrix and contains 300+ regulatory proteins.2-4


      Upon examination at his two month follow-up visit, the wound was fully closed and re-epithelialized. The patient returned for a routine one-year visit and has remained fully closed and asymptomatic.

      Following Debridement Four weeks of NPWT, only 30% size reduction, first DHACM 4 cm x 4 cm applied Week 2: Two 2 cm x 3 cm DHACM applied Week 4: One 2cm x 3 cm DHACM applied Week 8: Wound closed and stable

      Case Study 2

      Keloid Scar Revision With EPIFIX11

      Clinical History

      Patient presented with keloid after Caesarean section procedure.


      One third of the keloid scar was treated with DHACM (Dehydrated Human Amnion/Chorion Membrane) in revision surgery to evaluate its outcome prior to treating the remainder of the scar. DHACM was placed within the incision site before suturing.

      DHACM provides a barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. It provides a biocompatible human extracellular matrix and contains 300+ regulatory proteins.2-4


      The scar was greatly reduced in height and in color. Subsequent revision surgery treated the remainder of the keloid scar with DHACM.

      KELOID Scar Revision with DHACM Post-scar revision using DHACM on 1/3 portion of original scar Scar one year post DHACM treatment


      Plastic Reconstruction Casebook

      Surgical Product Portfolio: Advanced Placental-Based Allografts

      MIMEDX offers a portfolio of advanced placental-based allografts in the surgical setting.

      Complex Soft-Tissue Deficit
      Large Area Coverage
      Affix Product with Suture*
      Product Thickness Desired
      Exposed Bone, Tendon, or Hardware
      Reposition Product after Hydration
      Minimally Invasive Procedures
      Fenestrated Configuration to Allow Transfer of Exudate
      *Not intended for use as a load bearing tissue.


      1. Atkin L, Bućko Z, Conde Montero E, et al. Implementing TIMERS: the race against hard-to-heal wounds. J Wound Care. 2019;23(Sup3a):S1-S50.
      2. Koob TJ, Lim JJ, Massee M, Zabek N, Denozière G. Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. J Biomed Mater Res B Appl Biomater. 2014;102(6):1353-1362.
      3. Lei J, Priddy LB, Lim JJ, Massee M, Koob TJ. Identification of Extracellular Matrix Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane. Adv Wound Care (New Rochelle). 2017;6(2):43-53.
      4. MIMEDX Internal Report. MM-RD-00086, Proteome Characterization of PURION Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and PURION PLUS Processed Dehydrated Human Umbilical Cord (dHUC) Allografts.
      5. Bullard JD, Lei J, Lim JJ, Massee M, Fallon AM, Koob TJ. Evaluation of dehydrated human umbilical cord biological properties for wound care and soft tissue healing. J Biomed Mater Res B Appl Biomater. 2019;107(4):1035-1046.
      6. MIMEDX Internal Report. MM-RD-00113, Non-GLP Evaluation of Placental Based Products for Cellular Response in a Mouse Subcutaneous Implant.
      7. John Ko, MD, PhD, FACS, Plastic Surgery, Elmhurst, NY.
      8. Thombs BD, Singh VA, Halonen J, Diallo A, Milner SM. The effects of preexisting medical comorbidities on mortality and length of hospital stay in acute burn injury: evidence from a national sample of 31,338 adult patients. Ann Surg. 2007;245(4):629-634.
      9. Myles PS, Iacono GA, Hunt JO, et al. Risk of respiratory complications and wound infection in patients undergoing ambulatory surgery: smokers versus nonsmokers. Anesthesiology. 2002;97(4):842-847.
      10. Dunne JR, Malone DL, Tracy JK, Napolitano LM. Abdominal wall hernias: risk factors for infection and resource utilization. J Surg Res. 2003;111(1):78-84.
      11. Sanders R. Callaway, MD, Dermatology, Augusta, GA.